TY - JOUR
T1 - Bi-directional regulation between NAD/NAMPT and IFN-γ/PD-L1 axes via BRD4/IRF1 and mitochondrial respiration in metastatic cutaneous melanoma
AU - Fiorilla, Irene
AU - Ghezzi, Beatrice
AU - Ponzano, Alessia
AU - Moiso, Enrico
AU - Riccardo, Federica
AU - Tommasi, Nicoletta
AU - AVALLE, LIDIA
AU - Carrà, Giovanna
AU - Ugolini, Filippo
AU - Calussi, Edoardo
AU - Todesco, Alberto Maria
AU - Digiovanni, Sabrina
AU - Casone, Filippo
AU - Rizza, Giulia
AU - Ponzone, Luca
AU - Szumera-Ciećkiewicz, Anna
AU - CAVALETTO, Maria
AU - Porporato, Paolo Ettore
AU - Conti, Laura
AU - Riganti, Chiara
AU - Massi, Daniela
AU - Calautti, Enzo
AU - AUDRITO, VALENTINA
PY - 2026
Y1 - 2026
N2 - Background: Metastatic cutaneous melanoma (MCM) is primarily treated with BRAF/MEK inhibitors and immune checkpoint inhibitors (ICIs), but the long-term efficacy of these therapies is often limited by acquired resistance. Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in NAD biosynthesis, is frequently upregulated in MCM, supporting metabolic rewiring and targeted therapy resistance. Interferon-γ (IFN-γ) signaling plays a central role in melanoma biology, exerting both antitumor and immunoregulatory effects, linked with the onset of therapeutic resistance. Emerging evidence suggests that metabolic pathways may critically modulate IFN-γ responses; however, the functional interplay between NAD/NAMPT metabolism and IFN-γ signaling in melanoma cells remains poorly defined. Methods: We integrated transcriptomic, bioinformatic, biochemical, and functional approaches in human and murine melanoma cell lines, together with analyses of TCGA datasets and a tissue microarray (TMA) cohort. Mechanistic studies included pharmacological and genetic perturbation of Bromodomain and Extra-Terminal motif (BET) epigenetic factor BRD4, Interferon Regulatory Factor 1 (IRF1), and NAMPT, chromatin immunoprecipitation (ChIP) assays, and metabolic analyses. Tumor-T cell co-culture systems were used to assess the impact of melanoma-cell NAMPT modulation on T-cell behavior. Results: IFN-γ induced NAMPT expression through a BRD4/IRF1-dependent transcriptional program. In turn, NAMPT activity was required to sustain IFN-γ signaling, as its inhibition impaired STAT1 activation and downstream transcriptional responses. Mechanistically, NAMPT-dependent NAD metabolism supported mitochondrial complex I activity and oxidative metabolism and was required for efficient BRD4 recruitment to IFN-responsive promoters, including CD274/PD-L1 and NAMPT itself. Across melanoma datasets and patient samples, NAMPT expression correlated with IFN-γ-responsive genes, including PD-L1. Functionally, modulation of NAMPT in melanoma cells influenced T-cell cytotoxicity and migration in co-culture systems. Conclusions: Overall, these findings identify NAMPT as a key metabolic component of the IFN-γ response network in melanoma cells, establishing a feed-forward regulatory circuit linking cytokine signaling, chromatin regulation, and mitochondrial metabolism. This work provides a framework to investigate how metabolic control of IFN-γ signaling shapes tumor-immune interactions.
AB - Background: Metastatic cutaneous melanoma (MCM) is primarily treated with BRAF/MEK inhibitors and immune checkpoint inhibitors (ICIs), but the long-term efficacy of these therapies is often limited by acquired resistance. Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in NAD biosynthesis, is frequently upregulated in MCM, supporting metabolic rewiring and targeted therapy resistance. Interferon-γ (IFN-γ) signaling plays a central role in melanoma biology, exerting both antitumor and immunoregulatory effects, linked with the onset of therapeutic resistance. Emerging evidence suggests that metabolic pathways may critically modulate IFN-γ responses; however, the functional interplay between NAD/NAMPT metabolism and IFN-γ signaling in melanoma cells remains poorly defined. Methods: We integrated transcriptomic, bioinformatic, biochemical, and functional approaches in human and murine melanoma cell lines, together with analyses of TCGA datasets and a tissue microarray (TMA) cohort. Mechanistic studies included pharmacological and genetic perturbation of Bromodomain and Extra-Terminal motif (BET) epigenetic factor BRD4, Interferon Regulatory Factor 1 (IRF1), and NAMPT, chromatin immunoprecipitation (ChIP) assays, and metabolic analyses. Tumor-T cell co-culture systems were used to assess the impact of melanoma-cell NAMPT modulation on T-cell behavior. Results: IFN-γ induced NAMPT expression through a BRD4/IRF1-dependent transcriptional program. In turn, NAMPT activity was required to sustain IFN-γ signaling, as its inhibition impaired STAT1 activation and downstream transcriptional responses. Mechanistically, NAMPT-dependent NAD metabolism supported mitochondrial complex I activity and oxidative metabolism and was required for efficient BRD4 recruitment to IFN-responsive promoters, including CD274/PD-L1 and NAMPT itself. Across melanoma datasets and patient samples, NAMPT expression correlated with IFN-γ-responsive genes, including PD-L1. Functionally, modulation of NAMPT in melanoma cells influenced T-cell cytotoxicity and migration in co-culture systems. Conclusions: Overall, these findings identify NAMPT as a key metabolic component of the IFN-γ response network in melanoma cells, establishing a feed-forward regulatory circuit linking cytokine signaling, chromatin regulation, and mitochondrial metabolism. This work provides a framework to investigate how metabolic control of IFN-γ signaling shapes tumor-immune interactions.
KW - BET protein
KW - Inflammation
KW - Interferon
KW - Metastatic melanoma
KW - Mitochondrial respiration
KW - NAD
KW - NAMPT
KW - PD-L1
KW - Tumor microenvironment
KW - BET protein
KW - Inflammation
KW - Interferon
KW - Metastatic melanoma
KW - Mitochondrial respiration
KW - NAD
KW - NAMPT
KW - PD-L1
KW - Tumor microenvironment
UR - https://iris.uniupo.it/handle/11579/230982
U2 - 10.1186/s13046-026-03734-2
DO - 10.1186/s13046-026-03734-2
M3 - Article
SN - 0392-9078
JO - Journal of Experimental and Clinical Cancer Research
JF - Journal of Experimental and Clinical Cancer Research
ER -